| Autor: |
Florova B; Department of Clinical Biochemistry and Hematology, Faculty of Medicine in Pilsen, Charles University and University Hospital in Pilsen, Czech Republic. rajdl@fnplzen.cz., Rajdl D, Racek J, Fiala O, Matejka VM, Trefil L |
| Jazyk: |
angličtina |
| Zdroj: |
Physiological research [Physiol Res] 2020 Apr 30; Vol. 69 (2), pp. 307-317. Date of Electronic Publication: 2020 Mar 23. |
| DOI: |
10.33549/physiolres.934212 |
| Abstrakt: |
Cisplatin is a commonly used chemotherapeutic drugs. It is known for its nephrotoxic side effects with an increased risk of acute kidney injury. Finding of clinically feasible cisplatin nephrotoxicity markers is of importance. In our study, we compared neutrophil gelatinase-associated lipocalin (NGAL) in serum and urine, the estimated glomerular filtration rate (based on serum cystatin C) and urine albumin as markers of nephrotoxicity. The study involved 11 men and 9 women (mean ± SD age 58.2±9.5 years) with different malignancies treated with cisplatin in four cycles of chemotherapy (I - IV). Samples 0-4 were taken before, immediately after, in 3, 6 and 24 hours after administering chemotherapy. We detected significant increase of ACR in Sample 2 (p=0.03) and decrease of eGFR in Sample 4 (p=0.03) up to 24 hours after cisplatin administration in the first chemotherapy cycle only. When cumulative effect of cisplatin was assessed, significantly increased values of urine albumin (vs cycle I) were found in Sample 0 (p=0.00058), 1 (p=0.00256), 2 (p=0.00456), 3 (p=0.00006) and 4 (p=0.00319) in cycles II to IV. We found a correlation between values of urine NGAL and urine albumin (r=0.68, p<0.0001). In conclusion, urine albumin was the only measured marker that consistently and statistically significantly increased after cisplatin containing chemotherapy cycles. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
